Evidence map›Paper›PMID 40871097›Full record

ArticlePharmaceutics2025

Development of PBPK Population Model for End-Stage Renal Disease Patients to Inform OATP1B-, BCRP-, P-gp-, and CYP3A4-Mediated Drug Disposition with Individual Influencing Factors.

Yujie Wu, Weijie Kong, Jiayu Li, Xiaoqiang Xiang, Hao Liang, Dongyang Liu

Abstract read
In one paragraph

Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yujie WuDepartment of Nephrology, Peking University Third Hospital, Beijing 100191, China.
Weijie KongDepartment of Nephrology, Peking University Third Hospital, Beijing 100191, China.
Jiayu LiDepartment of Nephrology, Peking University Third Hospital, Beijing 100191, China.ORCID 0009-0001-6664-0559
Xiaoqiang XiangDepartment of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai 201203, China.ORCID 0000-0002-8683-2603
Hao LiangDepartment of Nephrology, Peking University Third Hospital, Beijing 100191, China.ORCID 0000-0003-4382-3704
Dongyang LiuDrug Clinical Trial Center, Peking University Third Hospital, Beijing 100191, China.ORCID 0000-0002-0608-8192

Funding

Capital's Funds for Health Improvement and Research CFH 2022-2Z-40917Gates Foundation INV-007625Key Clinical Projects of Peking University Third Hospital BYSYZD2024022
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

drug–drug–disease interactiondrug-metabolizing enzyme and transporterend-stage renal diseasepharmacokineticsphysiologically based pharmacokinetic modeling

Identifiers

PMID40871097
PMCPMC12389332

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.